Outcome of ABO‐incompatible kidney transplantation using a modified desensitization protocol without plasmapheresis
- 6 June 2022
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 29 (9) , 1017-1025
Abstract
Objectives: Several controversies regarding desensitization strategies for successful ABO‐incompatible (ABOi) kidney transplantation still exist. This study aimed to investigate whether pretransplant anti‐A/B antibody removal is mandatory in an ABOi kidney transplant recipient with low baseline isoagglutinin titers.Methods: We adopted a modified desensitization protocol with two doses of rituximab (RTX, 100 mg/body) without pretransplant antibody removal for ABOi kidney transplant recipients with a titer of ≤1:64 (group A; n = 35) and investigated the feasibility of this protocol by comparing it with the clinical outcomes of patients undergoing standard pretransplant plasmapheresis (group B; n = 21).Results: There was no significant difference in the rate of antibody‐mediated rejection within the first month after transplantation between the two groups (11.4% in group A vs. 2% in group B, p = 0.6019). Moreover, no differences were observed in the short‐ and long‐term graft outcomes between the groups. However, two major critical acute antibody‐mediated events occurred in group A; one patient lost the graft due to hyperacute rejection, and the other patient developed thrombotic microangiopathy after surgery. Risk factors predicting these perioperative complications were not identified.Conclusions: We conclude that not only B‐cell depletion using RTX but also pretransplant antibody removal is still recommended even for patients with low isoagglutinin titers. In addition, a new diagnostic tool is needed for accurate risk stratification.Keywords
This publication has 24 references indexed in Scilit:
- Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody‐mediated diseaseBritish Journal of Clinical Pharmacology, 2013
- Transplant Accommodation—Are the Lessons Learned from Xenotransplantation Pertinent for Clinical Allotransplantation?American Journal of Transplantation, 2012
- The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experienceClinical Transplantation, 2010
- Accommodation in renal transplantation: unanswered questionsCurrent Opinion in Organ Transplantation, 2010
- ABO Antibody Titer and Risk of Antibody‐Mediated Rejection in ABO‐Incompatible Renal TransplantationAmerican Journal of Transplantation, 2010
- Identification and Characterization of Major Proteins Carrying ABO Blood Group Antigens in the Human KidneyTransplantation, 2009
- Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipientsTransplant International, 2009
- Banff 07 Classification of Renal Allograft Pathology: Updates and Future DirectionsAmerican Journal of Transplantation, 2008
- Japanese Experience of ABO-Incompatible Living Kidney TransplantationTransplantation, 2007
- Excellent Long-term Outcome of ABO-Incompatible Living Donor Kidney Transplantation in JapanAmerican Journal of Transplantation, 2004